Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

…

04 April 2025 Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer  Approval based on AEGEAN Phase III trial…

04 April 2025 Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer…

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the…

International pharma stocks GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) may have dodged a bullet under Donald Trump’s sweeping new tariff...…

UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that...…

AstraZenecas new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.…

31 March 2025 Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line…

31 March 2025 Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer  Based on NIAGARA Phase III…

…

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust…

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street…

In the most recent trading session, Astrazeneca (AZN) closed at $72.72, indicating a -0.45% shift from the previous trading day.…

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly…

Pharmaceutical company will invest money over five years in ‘strategic partnership’ with the city’s authorities…

Der britische Pharmakonzern baut seine Präsenz im chinesischen Markt mit einem 2,5-Milliarden-Dollar Forschungszentrum in Peking aus, was Anleger vorerst skeptisch…

AstraZeneca has shown its commitment to China amid investigations into its executives and activities,…

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the…

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals…

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing,…

AstraZeneca to invest $2.5 billion in new Beijing R&D center…

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker…

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker…

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has completed two major projects for AstraZeneca PLC (LSE:AZN), expanding the use of its Parsortix liquid biopsy…

The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.…

Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential…

The European Commission approves AstraZenecas Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.…

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or…

European stocks rise on German debt deal hopes; AstraZeneca in focus…

AstraZeneca has announced an agreement to acquire EsoBiotec, securing the biotechnology firm’s pioneering in vivo cell therapy platform that has…

Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion.…

The Trump administration has unnerved investors with its departure from traditional trade policy. The average tax on U.S. imports fell…

AstraZeneca befindet sich an einem entscheidenden Punkt, während die Pharmamärkte mit sich entwickelnden wirtschaftlichen Belastungen und veränderter Anlegerstimmung konfrontiert sind.…

In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.…

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 14200…

7 March 2025 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 6 March 2025, an award of…

AstraZeneca PLC has edged closer to its aim of generating $80 billion in revenue come 2030 on positive results from…